Erythrocytes are known to influence hemostasis. Bleeding times are prolonged in anemia and corrected by normalizing the hematocrit. We now demonstrate that intact erythrocytes modulate biochemical and functional responsiveness of activated platelets. A two-stage procedure, permitting studies of cell-cell interactions and independently evaluating platelet activation and recruitment within 1 min of stimulation, was developed. Erythrocytes increased platelet serotonin release despite aspirin treatment, enzymatic adenosine diphosphate removal, protease inhibition, or combinations thereof. The data suggested that erythrocyte enhancement of platelet reactivity can reduce the therapeutic effectiveness of aspirin.
devised an experimental system to study cell-cell interactions and independently evaluate platelet activation and platelet recruitment (2, 3) as separate components of platelet reactivity. Platelets, combined suspensions of platelets with other cells, or even whole blood are stimulated (generating system), immediately centrifuged and the separated cell-free releasate studied biochemically. In addition, the releasate can be added to human platelet-rich plasma (PRP)' (assay system) where it acts as agonist for initiation and evaluation of recruitment ( Fig. 1) .
Previous concepts of erythrocyte participation in hemostatic and thrombotic events focused on mechanical liberation of proaggregatory substances (4) . In contrast, we found that metabolically active, intact erythrocytes enhanced platelet activation and recruitment.
Eicosanoid metabolism is modulated by cell-cell interactions wherein precursors, intermediates and metabolic end products can be processed by different cells in close apposition and under different stimulatory conditions (5) . We therefore examined metabolism of platelet arachidonate and eicosapentaenoate (a biologically active w-3 fatty acid derived from fish oil) when platelets were activated alone or in combination witherythrocytes in the presence or absence ofaspirin. Erythrocytes considerably modified platelet eicosanoid metabolism and functional responsiveness. The rapid cell-cell interactions described herein have not been heretofore characterized.
Methods
Platelet and erythrocyte collection and processing. Cell suspensions were prepared from 160 ml of blood, collected by free flow in plastic tubing through a 1 5-gauge needle (6) . 50-ml polypropylene tubes were used, two of which contained 4.5 ml of 3.8% sodium citrate in a total volume of 45 ml. Two others contained 6 ml of acid-citrate-dextrose (ACD; 38 mM citric acid, 75 mM sodium citrate, and 135 mM glucose) in a total volume of 46 ml. Blood was centrifuged at 200 g to obtain PRP. The PRP, prepared with citrate (adjusted to a platelet count of 4-5 X 108/ml with platelet-poor plasma) was capped and maintained at 220C under 5% C02-air, for use as the assay system for platelet aggregation (6) . Platelets in the ACD-anticoagulated tubes were washed and labeled as described below. Washed platelets were used in the generating system to be stimulated by agonists in the presence and absence of washed erythrocytes.
After removal of PRP from the citrate-anticoagulated tubes, the buffy coat was aspirated and discarded. 10 ml of erythrocytes were 1. Abbreviations used in this paper: ACD, acid citrate dextrose (USP Formula A); ASA, acetylsalicylic acid; CP, creatine phosphate; CPK, creatine phosphokinase; EPA, eicosapentaenoic acid; 12-HHTE, 1 2(S)-hydroxyheptadecatetraenoic acid; 1 2-HHTrE, 1 2(S)-hydroxyheptadecatrienoic acid; 1 2-HEPE, 1 2(S)-hydroxy-5,8-cis, 10-trans, 14,1 7-cis-eicosapentaenoic acid; 12-HETE, 12(S)-hydroxy-5,8-cis, 10 -trans, 14-cis-eicosatetraenoic acid; 5-HT, serotonin; LDH, lactic dehydrogenase; PRP, platelet-rich plasma.
Generating System (Activation) removed from the central area of the erythrocyte zone with a plastic pipette. Erythrocytes were distributed in 3-ml aliquots and 7 ml of phosphate-buffered saline, containing glucose (NaCl 130.9 mM, Na2HPO4 5.1 mM, KH2PO4 1.50 mM, glucose 83 mM, pH 7.2) were added to each aliquot. After gentle inversion, the erythrocyte suspension was centrifuged at 200 g (10 min, 220C) and the procedure repeated. At Products, Boston, MA) were converted to the sodium salt with Na2CO3 and transferred to the platelet suspension (6) . Labeling was carried out for 45 min with gentle shaking (37°C). The sample was cooled on ice (10 min), transferred to calibrated conical tubes, and centrifuged at 1,450 g for 15 min (4°C). The washing procedure was repeated once. Final suspension was in cold 0.9% NaCl. The platelet count was adjusted to 109/ml. Scintillation counting was performed on a 20-,l aliquot from the adjusted platelet suspension. Uptake of label averaged 57% for arachidonate and 48% for eicosapentaenoate. Systemfor independent evaluation ofplatelet activation and recruitment. Fig. 1 depicts the two-stage in vitro system used. Agonists were added to the generating system to activate platelets or combined suspensions ofplatelets and erythrocytes. The cell-free releasate obtained after centrifugation ofthe generating system was, within 1 min, either transferred to the assay system (PRP) for assessment ofproaggregatory activity (recruitment) or used for biochemical studies to assess activation.
The generating system (1 ml in total volume) consisted of0.2 ml of washed platelets containing 1 X 109/ml, 0.4 ml of phosphate-buffered saline, and 0.4 ml of packed erythrocytes or buffer controls. This was preincubated for 10 min at 37°C before agonist addition. After addition of agonist, the tube was inverted three times (10 s), followed by centrifugation (Eppendorf, Brinkmann Instruments Co., Westbury, NY) at 10,000 g for 50 s. The cell-free supernatant (releasate) was immediately transferred (50 Ml) to the PRP assay system in an aggregometer, to serve as agonist for platelet aggregation (recruitment). The assay system consisted of 125 Ml ofPRP containing 4-5 x I0O platelets/ ml, 100 M' of phosphate-buffered saline and calcium (final concentration 1 mM). With collagen, there was no carryover ofagonist from the generating system since it sedimented during centrifugation. Carryover of thrombin and ionophore had no appreciable effect in the assay system (see Fig. 3 the generating system 1 min before agonist in specified experiments. Platelets and erythrocytes were studied in the physiological range, i.e., 2 X 0I platelets/ml and erythrocytes at 40% hematocrit.
Lipid analyses. Cell-free releasate (400 Ml) was brought to pH 3.5 with 1 M citric acid, 1.4 ml chloroform/methanol (2:5) added, and the polypropylene tube vortexed. Samples could be stored at -70°C, before modified Bligh and Dyer extraction (6) . Final extracts were dried 572 Santos et al.
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under nitrogen, dissolved in 0.1 ml chloroform/methanol (2:1) and aliquots removed for scintillation counting. Thin-layer chromatography, scanning, and quantitation have been described (6) .
Procedures for evaluation ofcell integrity. Two methods were employed to verify that results were not due to loss of cell integrity.
Washed platelets alone with collagen (16 Ag/ml), thrombin or vehicle all showed 0.2% lactate dehydrogenase (LDH) release (measured as described [7] ). lonophore induced 0.79% LDH release and the ethanol vehicle 0.33%. Platelet-erythrocyte mixtures in buffer showed 0.07% LDH in the supernatants, and this remained constant with collagen and thrombin stimulation. With ionophore, 0.1 1% LDH was noted.
Hemoglobin content of supernatants from samples containing erythrocytes was measured spectrophotometrically at 576 and 540 nm. Supernatants oferythrocytes alone in buffer contained 0.05% hemoglobin. With 0.1% ethanol, 0.23% hemoglobin was present. Aspirin had no effect on supernatant hemoglobin or LDH values. In no instance did platelet activation induce hemoglobin or LDH release from erythrocytes.
Results
Effect of intact erythrocytes on platelet activation and recruitment. Stimulation ofplatelets in the presence ofintact erythrocytes in the generating system ( Fig. 1 ) resulted in marked enhancement of platelet activation, as indicated by 5-HT release (Fig. 2) . Erythrocyte amplification of platelet reactivity was also reflected in the ability ofthe cell-free releasate, when used as agonist, to induce an increased aggregation response in the PRP assay system (recruitment) (Fig. 3) .
Addition of collagen (16 ,g/ml) to platelets alone evoked 34% 5-HT release (Fig. 2) . This rose to 81% release in the presence of erythrocytes. Aspirin reduced the collagen response to 15%, but with added erythrocytes release increased to 56%.
The amplifying effect of erythrocytes was lower with the soluble agonists, thrombin and especially ionophore, as compared to collagen (Fig. 2) . Erythrocyte enhancement (expressed as percentage of control) was similar, even with lower concentrations of thrombin (0.1, 0.3 U/ml) or ionophore (0.5 sM).
Releasates from platelets alone and from platelet-erythrocyte suspensions were also tested in the PRP assay system for recruitment (Fig. 3 ). When collagen (4 ,ug/ml) was added to platelets alone in the generating system, an aliquot ofreleasate, transferred to the PRP assay system, induced aggregation with a maximal amplitude of 26±7 mm (mean±SEM). However, releasates from platelets plus erythrocytes, resulted in enhanced recruitment, with aggregation curves of 62±9 mm (P < 0.01). The erythrocyte-amplifying effect on platelet recruitment with 16 qg/ml collagen (Fig. 4 ) was less than that at 4 ,Ug/ml.
Control experiments defined absolute requirements for releasates from the generating system to induce recruitment in the PRP assay system (Fig. 3) . Erythrocytes must interact with activated platelets for enhancement to occur. Supernatants from unstimulated platelet-erythrocyte mixtures, or from erythrocytes alone exposed to agonists did not induce recruitment, or 5-HT release. In additional control experiments, freshly prepared, washed erythrocytes were compared with glutaraldehyde-treated, ATP-depleted erythrocytes (8) . In contrast to fresh erythrocytes, glutaraldehyde-treated erythrocytes had no enhancing effect on platelet activation or recruitment. Thus, metabolic integrity oferythrocytes is required for the cell interactions under study.
Releasates from platelets stimulated by thrombin or ionophore in most instances induced reversible aggregation. Inclusion of intact erythrocytes markedly increased recruiting properties of releasates, resulting in irreversible aggregation (Fig. 3) .
Aspirin ( Effects ofenzymatic removal ofADP in the generating system on platelet-erythrocyte interactions. Since erythrocyte-derived ADP has been implicated as an agonist for platelet function (9), we studied the generating system in its absence. Serotonin release from collagen-stimulatdd platelets was reduced by apyrase or CP/CPK (Fig. 5 ). Nevertheless, ADP removal did not affect erythrocyte enhancement of collagen-stimulated 5-HT release. ADP removal from thrombin-and ionophorestimulated platelets alone or platelet-erythrocyte mixtures did not affect 5-HT release. Erythrocyte enhancement took place with all agonists, and was most pronounced with collagen. Therefore enhancement of platelet activation by erythrocytes was not primarily mediated by ADP, nor was released platelet ADP required to elicit the erythrocyte effect (Fig. 5 ). The effects of ADP removal on platelet recruitment (Table I) were much more pronounced than those on platelet activation, especially with collagen. ASA treatment was superimposed upon removal of ADP from the generating system to establish (a) whether erythrocytes still reacted to material released from platelets in the absence of both TXA2 and ADP, and (b) whether these platelets still responded to erythrocytes. In the collagen-stimulated, ASA-treated, ADP-free generating system, 5-HT release in platelets alone was markedly reduced, but erythrocyte enhancement still occurred (Fig. 5) (Table II) . This protease inhibitor effect occurred with collagen in untreated platelet-erythrocyte mixtures (18% reduction), as well as those pretreated with aspirin plus apyrase (33% reduction) when compared with vehicle controls (Table  II) . These data suggest participation ofprotease activity in platelet-erythrocyte interactions in samples stimulated with collagen (P < 0.005), but not ionophore. Since the PMSF component of the protease inhibitor mixture would directly affect thrombin by sulfonylating the active site serine, parallel experiments with thrombin were not performed.
Eicosanoid metabolism during platelet-erythrocyte interactions. When [3H]arachidonate-labeled platelets were activated with collagen and thrombin, erythrocytes strongly amplified arachidonate release (Table III) . Amplification of release was more pronounced with collagen than thrombin. Platelet release of [3H] arachidonate by ionophore exceeded that of collagen and thrombin fivefold (Table III) . In contrast to collagen and thrombin, ionophore-induced arachidonate release was unchanged by erythrocytes.
ASA pretreatment reduced arachidonate release induced by collagen (10, 11) , thrombin, and especially ionophore (Table  III) . The aspirin-induced reduction of arachidonate release in platelets alone was overcome by erythrocytes with each agonist (Table III) . Notably, erythrocytes promoted the same arachidonate release as platelets alone in the absence of aspirin.
Patterns ofarachidonate transformation in platelets alone. Fig. 6 ). With ASA-treated platelets alone, production of 1 2-HETE and free arachidonate were reduced at 1 min (compare Table IV and Fig. 6 ), reflecting the decrease in total radioactivity released in the presence of aspirin (Table III) .
Erythrocyte modification ofplatelet eicosanoid production.
Erythrocytes exerted stimulus-specific alterations in eicosanoid profiles ofcell-free releasates. However, erythrocytes induced a marked increase in free arachidonate with all three agonists (Fig. 6, Table IV ).
Erythrocyte amplification of platelet TXB2 and 12-HHTrE was very prominent with collagen, modest with thrombin and Figure 4 . Effect of ASA on recruiting activity (aggregation response in PRP) of cell-free releasates from platelets or platelets plus erythrocytes in the generating system (Fig. 1) . Collagen 16 ,gg/ml, thrombin 1 U/ml or ionophore 2 gM; mean+SEM; n = 5-11. *P < 0.025; **P < 0.005, platelets vs. platelet-erythrocyte mixtures, untreated or ASA-treated. (i) Platelets; (a) platelets plus erythrocytes; (o) aspirintreated platelets; (i) aspirin-treated platelets plus erythrocytes. Mean±SEM, n = 5; collagen 16 ug/ml, P < 0.005 for platelets vs. platelet-erythrocyte mixtures (paired t test); thrombin I U/ml, P < 0.01; ionophore 2 MM, P < 0.05; apyrase 2 U/ml; CP 5 mM; CPK 40 U/ml; aspirin 1 mM.
did not occur at all with ionophore (Fig. 6 ). The increment of platelet 1 2-HETE production by erythrocytes was 1.6-fold for collagen and 1.2-fold for thrombin. However, with ionophore erythrocytes actually inhibited 12-HETE production by onehalf (Fig. 6) .
As in the ASA-free system, the most prominent effect of erythrocytes in the presence of ASA was a marked increase in free arachidonate induced by all agonists (Table IV) . Erythrocytes enhanced 1 2-HETE production with collagen and thrombin, but with ionophore a reduction was once again observed (Table IV) .
These results demonstrate strong modulating effects of erythrocytes on platelet eicosanoid formation during the first minute of stimulation.
EPA metabolism during platelet-erythrocyte interactions.
With EPA-labeled platelets alone, EPA release with collagen and thrombin was similar, but was about threefold greater with ionophore (Table V) .
Release of EPA in the presence of erythrocytes was enhanced more with collagen than with thrombin as compared to platelets alone (Table V) . Enhancement was similar to that with arachidonate-labeled platelets (Table III) . Erythrocytes did not enhance ionophore-induced EPA release, again comparable to arachidonate (Tables III and V) . Released radioactivity with ionophore in platelet-erythrocyte mixtures was lower with EPA than with arachidonate.
Aspirin reduced EPA release from stimulated platelets in the presence or absence oferythrocytes (Table V) . Under these circumstances, erythrocytes also enhanced release of EPA with collagen and thrombin, as with arachidonate. However, with ionophore, the ASA-induced decrease in radioactivity in platelets alone was not reversed by erythrocytes, in contrast to results with arachidonate-labeled platelets (compare Tables III  and V) .
EPA released from platelets alone by each agonist was preferentially processed by lipoxygenase (Table VI) . This differed from arachidonate with collagen and thrombin, where cyclooxygenase products predominated (Fig. 6 ). In the arachidonate-ASA experiments, 12-HETE and free arachidonate were reduced as compared to ASA-free controls (compare Table IV and Fig. 6 ). In contrast, in the EPA-ASA experiments, 12-HEPE (see footnote 1) and free EPA were essentially unaffected by ASA (compare Tables VI and VII) .
Erythrocytes significantly altered the EPA-derived eicosanoid profiles with each agonist (Table VI) . With ionophore, erythrocytes markedly decreased platelet 12-HEPE; with collagen, TXB3 and 12-HHTE (see footnote 1) were enhanced. As with arachidonate, free platelet EPA was dramatically increased by platelet-erythrocyte contact with each agonist (Table VI).
Upon ASA treatment, erythrocytes inhibited platelet 12-HEPE production drastically with ionophore but not signifi- cantly with collagen and thrombin. Erythrocytes again promoted a substantial increase in free EPA with each agonist (Table VII) . Thus, erythrocytes induced distinct differences in eicosanoid metabolism when platelets were labeled with EPA or arachidonate, especially in the lipoxygenase pathway. Erythrocytes increased 12-HETE formation with and without ASA treatment with collagen and thrombin. In sharp contrast, erythrocytes did not increase 12-HEPE production from EPA in the same setting. Results with ionophore were unique: erythrocytes markedly reduced production of 12-HETE and especially 12-HEPE (compare Fig. 6 and Tables IV, VI, and VII). Erythrocyte effects on cyclooxygenation and promotion of free fatty acid accumulation were similarly pronounced in EPA-and arachidonate-labeled platelets.
Discussion
The system developed for independent evaluation of platelet activation and recruitment serves as an in vitro model of early hemostatic and thrombotic events. It focuses on early time points and allows for measurement ofbiochemical and physiological parameters associated with activation and cell contact (Fig. 1) . Intact erythrocytes enhanced platelet reactivity, as evidenced by activation (5-HT release) in the generating system (Figs. 2 and 5), and platelet recruitment (aggregation) induced by releasates added to the PRP assay system (Figs. 3 and 4) . Platelet activation and intact erythrocytes were required for induction of the enhancing effect (Fig. 3) . Whereas erythrocyte-derived ADP may play a role in platelet function in specific situations, as previously described (9, 12), our data unequivocally demonstrated that erythrocyte enhancement of platelet reactivity proceeded in the complete absence of released ADP (Fig. 5) .
Enhancement was greater with collagen than with thrombin or ionophore (Fig. 2) . This may be relevant to the chronology of an accumulating platelet thrombus in vivo. Platelets are initially exposed to collagen at sites ofinjury. Therefore erythrocyte enhancement of platelet reactivity would be functionally important at this early phase in hemostasis. Thrombin, which forms subsequent to collagen contact, induced twice as much activation with platelets alone as did collagen (Fig. 2) . However, erythrocyte enhancement of platelet activation was lower with thrombin than with collagen, but could also support thrombus formation.
Partial reversal oftheASA-inducedplatelet activation defect by erythrocytes. Erythrocyte enhancement of ASA-treated platelet activation occurred with all three agonists despite ab- (Fig. 2) . However, overall activation fell short of that achieved by stimulating untreated platelets plus erythrocytes. These results pertain to aspirin as a therapeutic modality. Ifplatelets receive sufficient stimulation to overcome ASA inhibition, erythrocytes still augment activation. Erythrocyte promotion ofplatelet reactivity may in part explain the more modest therapeutic effects of aspirin than expected on the basis of experiments with platelets alone. Platelet-erythrocyte interactions in the presence ofprotease inhibitors. Since ASA-treatment and/or ADP removal did not abolish erythrocyte enhancement ofplatelet activation (Fig. 5) , we extended and combined these experiments with protease inhibition. Association ofprotease activity with platelet activation is well documented (13) (14) (15) . Proteolytic activity played a significant role during platelet-erythrocyte interactions with collagen (Table II) . Protease inhibition reduced 5-HT release in platelet-erythrocyte suspensions, but not in collagen-stimulated platelets alone. Agonists were added to [3H]arachidonate-labeled platelets (2 X I08/ ml) or to platelet-erythrocyte mixtures (40% hematocrit) in the presence of ASA (1 mM) in the generating system. Eicosanoids were isolated, separated, and quantified by thin-layer chromatography and scanning. Values are expressed as total counts per thin-layer chromatographic peak; n = 6-10.
* Collagen (16,gg/ml); thrombin (I U/ml); ionophore (2 PM).
* P < 0.025; f P < 0.005 using paired t test (platelets vs. platelets plus erythrocytes).
Participation of protein kinase C in erythrocyte enhancement of platelet responsiveness was evaluated in preliminary experiments (data not shown), using staurosporine (1 gM) (16) .
After stimulation with each agonist, release of5-HT from platelets alone was strongly inhibited, but in each instance erythrocytes enhanced platelet activation. Erythrocyte amplification also occurred when platelets were simultaneously treated with staurosporine, ASA, and enzymatic removal of ADP.
Thus, systematic treatment ofplatelet-erythrocyte mixtures with inhibitors of platelet activation, alone or in combination, was insufficient to abolish erythrocyte enhancement effects. We conclude that erythrocyte enhancement may involve not only known, but also as yet unidentified pathways of platelet activation.
Effect oferythrocytes on platelet arachidonate and EPA release. Erythrocytes strongly influenced release and metabolism of platelet arachidonate and EPA with agonist and substrate specificity. They induced a selective enhancement of platelet phospholipase activity and/or an overall increase in platelet activation, since, with collagen and thrombin, they increased release of both arachidonate and EPA.
In contrast, with ionophore erythrocytes did not enhance arachidonate or EPA release. Arachidonate or EPA may already have been fully mobilized, since ionophore induced three-to fivefold greater fatty acid release than collagen or thrombin in platelets alone (Tables III and V) . However, platelet incorporation ofarachidonate and EPA were similar, as was release induced by collagen and thrombin. In contrast, ionophore-induced release was 1.6-fold less for EPA than arachidonate (Tables III and V) . This suggested that the releasable pool of EPA was not "metabolically exhausted." Alternatively, ionophore could have acted on erythrocytes (17, 18) , as well as platelets, thereby initiating eicosanoid metabolism in this cellcell interaction via different mechanisms than collagen or thrombin.
As with 5-HT release, cyclooxygenase activity was not essential for erythrocyte promotion ofarachidonate release. Furthermore, ADP removal did not impede erythrocyte enhancement of arachidonate release or subsequent metabolism (data not shown). Thus, two important pathways of platelet responsiveness are not critical components ofthe platelet-erythrocyte interactions reported here.
Eicosanoid metabolism ofplatelets alone. Stimulated platelets alone converted > 80% ofreleased arachidonate or EPA to metabolites (Fig. 6 , Table VI ). TXB2 and 12-HHTrE were the major arachidonate products with collagen and thrombin. Unexpectedly, ionophore activated lipoxygenase to a much greater extent than cyclooxygenase (Fig. 6) . Two explanations seem plausible: (a) since much more substrate was released by ionophore, cyclooxygenase activity may have self-inactivated before 1 min (19, 20) , permitting a greater degree oflipoxygenation; or (b) released arachidonate could have originated from different pools with different accessibilities to their metabolizing enzymes (21).
Released EPA was preferentially metabolized to 12-HEPE with each agonist, especially ionophore (Table VI) . Increased conversion of EPA to 1 2-HEPE as compared with arachidonate to 12-HETE was reported (22, 23) , and may be related to lesser affinity ofcyclooxygenase for EPA than for arachidonate (22) . Furthermore, lipoxygenase has a greater capacity for conversion of EPA than for arachidonate (23) .
Stimulus-specificity ofplatelet eicosanoid profiles as regulated by erythrocytes. Our data demonstrate for the first time that intact erythrocytes regulate qualitative and quantitative production ofeicosanoids by stimulated platelets in an agonistspecific manner. Since collagen is the first agonist with which platelets come into contact during hemostasis, the dramatic promotion of TXA2 formation and arachidonate release and accumulation by erythrocytes at 1 min (Fig. 6 ) is important, because of their significant roles in platelet activation and recruitment (24) . These early erythrocyte amplification events Collagen-stimulated cell mixtures generated more than twice the TXA2 and 12-HHTrE than did thrombin, despite similarly enhanced availability of free arachidonate. The high ratio between free arachidonate and TXB2 induced by thrombin as compared to collagen demonstrates an erythrocyte-dependent, agonist-specific effect on platelet cyclooxygenase. A similar effect occurred with EPA metabolism.
After ASA treatment, erythrocytes resulted in greater 12-HETE production with collagen than thrombin, but arachidonate accumulation was similar, again emphasizing stimulus specificity of the erythrocyte effect (Fig. 6, Table IV) .
Erythrocytes modulated platelet eicosanoid production in a unique manner with ionophore (Fig. 6) . Releasates from ionophore-stimulated platelets alone contained far greater quantities ofeicosanoids (more than threefold), than those from collagen-or thrombin-activated platelets. Nevertheless, no amplification of platelet eicosanoid formation by erythrocytes occurred, despite availability of free arachidonate. In fact, erythrocytes markedly reduced 1 2-HETE formation with ionophore (Fig. 6) (25, 26) . Reduction of 12-HEPE might counteract some of the beneficial effects of EPA. On the other hand the increase in TXB3 with collagen and thrombin may be therapeutically beneficial (27) (28) (29) . The pronounced enhancement of free EPA accumulation (Tables VI, VII) is offunctional importance since EPA, in contrast to arachidonate is not proaggregatory (29, 30) . Free EPA competes with arachidonate and leads to production of eicosanoids with different biological properties. Erythrocyte-induced enhancement of free EPA accumulation will therefore contribute to the action of EPA as an anti-thrombotic and anti-inflammatory agent.
Activation and recruitment as separate expressions ofplatelet reactivity. Although activation and recruitment often occur in parallel, there was a wide divergence between these two parameters in at least three experimental settings. (a) Upon ASA treatment and ionophore stimulation, activation far exceeded recruitment (Figs. 2, 4) . Although arachidonate in the releasate should, theoretically, have contributed to recruitment, it did not do so in a major way. This was demonstrated in a comparison of assay systems which were either ASA treated, or ASA free (data not shown). We conclude from the results in Fig. 4 that, in the case of ionophore, arachidonate transfer was not sufficient to stimulate the platelets in the assay system. We speculate that thrombin-and collagen-activated releasates contain a component necessary to induce recruitment, which is not present in ionophore-activated releasates (Fig. 4) . Alternatively, ionophore stimulation may directly or indirectly yield an inhibitory component. (b) When ADP was enzymatically removed, activation by collagen and thrombin was minimally affected, but recruitment was greatly reduced (Table I) . (c) With collagen, erythrocyte enhancement was dose-dependent.
At 4 gg/ml enhancement of recruitment was proportionately greater than at 16 ,g/ml (Figs. 3 and 4) , but the reverse was true for activation (data not shown).
Clinical implications of these data relate to interpretations ofmeasurements ofplatelet activation in body fluids (eg metabolites of eicosanoids such as TXA2). Elevated levels have been correlated with clinical thrombotic events. If activation occurred with minimal recruitment, these correlations may require re-evaluation.
In conclusion, we developed a two-stage in vitro system to study initial events in human platelet activation and recruitment independently. These two phenomena do not always occur in parallel. Cell-free releasates from platelets in the presence of erythrocytes had greater recruitment capacity than those from stimulated platelets alone. Intact erythrocytes in the presence of activated platelets: first, enhanced platelet activation, even in the setting of aspirin treatment, ADP removal and/or protease inhibition; secondly, increased platelet arachidonate or eicosapentaenoate mobilization after collagen or thrombin stimulation, with or without aspirin or ADP re-moval; thirdly, modulated cyclooxygenase and lipoxygenase metabolite formation in a stimulus-specific manner; and fourthly, increased accumulation of free arachidonate or eicosapentaenoate in the cellular environment. These studies provide a metabolic basis for the recognized participation of erythrocytes in hemostasis and thrombosis, and emphasize the importance of considering these processes as multicellular events.
